Probiotic Interventions in Antibiotic-Associated Diarrhea: Mechanistic Insights, Therapeutic Efficacy, and Emerging Nanotechnological Formulations

Antibiotic-associated diarrhea (AAD) is a common adverse effect of antibiotic therapy, primarily resulting from gut microbiota disruption. Probiotics have emerged as promising agents to restore intestinal microbial balance and support gastrointestinal health, yet uncertainties remain regarding their mechanisms, strain-specific efficacy, and clinical optimization. This review evaluates the role of probiotics in the prevention and management of AAD, analyzes their clinical efficacy, and explores microbial insights to guide future probiotic interventions. A systematic review of randomized controlled trials, meta-analyses, and microbiome-based studies was performed. Key parameters, including probiotic strain specificity, dosage, treatment duration, and safety, were assessed through data synthesis from clinical and microbiome analyses. Probiotics were found to restore gut microbial diversity, strengthen mucosal barrier function, and modulate immune responses. Evidence supports that Lactobacillus rhamnosus GG and Saccharomyces boulardii effectively reduce the incidence of AAD. Emerging approaches involving personalized probiotic therapy based on individual microbiota profiles demonstrate potential benefits, though heterogeneity in trial design and formulations remains a challenge. Probiotics represent an effective adjunct in AAD prevention and management. Future research should prioritize strain-specific, personalized clinical trials and develop standardized guidelines incorporating microbiome profiling to optimize probiotic selection and therapeutic outcomes.